-
Most physicians reported in a national survey that they would discuss end-of-life options with a terminally ill patient only when there were no more treatments to offer that patient, not when the patient still was feeling well, according to a study published online in CANCER, a peer-reviewed journal of the American Cancer Society.
-
"It should look like Grandma's house."
-
-
FDA is reviewing safety of TZDs; SSRI use with tamoxifen; Metformin smells like fish; FDA Actions.
-
-
In an analysis of community-performed colonoscopies in southwestern Germany, the prevalence of left-sided advanced colorectal neoplasms, but not right-sided neoplasms, was strongly reduced within a ten-year period after colonoscopy.
-
The patient is an 82-year-old woman referred for management of newly diagnosed breast cancer. She had been well until approximately 10 years prior to this evaluation, when she sustained a myocardial infarction from which she recovered without complication. Subsequently, she was found to have moderate hypertension and hyperlipidemia, which has been managed medically.
-
The activation mutation JAK2 tyrosine kinase (JAK2V617F) is found in 50% of patients with myleofibrosis (MF). In this phase-2 study, CEP 701, a JAK2 inhibitor, was administered to MF patients harboring a JAK2 mutation.
-
The seven-year update of IRIS (a phase-3 International Randomized Study of Interferon and STI571), which randomized chronic-phase CML (CP-CML) patients to IFNa/AraC or imatinib (400 mg/d), showed an 81% EFS and 86% OS for imantinib.
-